Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

We report a novel phase 2 clinical trial in patients with poor prognosis refractory non-Hodgkin lymphoma (NHL) testing the efficacy of haploidentical donor natural killer (NK) cell therapy (NK dose 0.5–3.27 × 10(7) NK cells/kg) with rituximab and IL-2 (clinicaltrials.gov NCT01181258). Therapy was to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Bachanova, Veronika, Sarhan, Dhifaf, DeFor, Todd E., Cooley, Sarah, Panoskaltsis-Mortari, Angela, Blazar, Bruce R., Curtsinger, Julie M., Burns, Linda, Weisdorf, Daniel J., Miller, Jeffrey S.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055922/
https://ncbi.nlm.nih.gov/pubmed/29218366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-2100-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados